Sponsors running Latin America medical device clinical trials in 2026 face five distinct national regulators, each with its own timelines, dossier expectations, and ethics-committee interfaces. This guide compares INVIMA (Colombia), ANVISA (Brazil), COFEPRIS (Mexico), ANMAT (Argentina), and MINSA (Panama) across the variables that actually move time-to-first-patient-in (FPI): submission pathway, review clock, ethics workflow, importation permit, and post-approval obligations.
At-a-glance comparison
| Country | Regulator | Median regulatory clock | Ethics review | Import permit | Legal rep required |
|---|---|---|---|---|---|
| Colombia | INVIMA | 4–6 months | CEI (parallel with INVIMA) | Yes (INVIMA-issued) | No |
| Brazil | ANVISA | 6–10 months | CEP/CONEP (sequential) | Yes (LI + RDC 39) | Yes (Brazilian sponsor rep) |
| Mexico | COFEPRIS | 5–8 months | CEI + CI (parallel allowed) | Yes (Permiso Sanitario) | Yes (Mexican rep) |
| Argentina | ANMAT | 5–7 months | CEI + provincial (dual-track) | Yes (Disp. 4457) | Yes |
| Panama | MINSA | 3–5 months | CNBI | Yes (MINSA) | Yes |
Colombia — INVIMA
INVIMA operates under Resolution 2378/2008 (GCP) and Decree 582/2017 for medical device studies. Parallel CEI + INVIMA filing is the standard bioaccess® pattern, compressing FPI to 4–6 months for Class IIb/III devices. Import permits are issued alongside the study authorization.
Brazil — ANVISA
ANVISA’s Dossiê de Investigação Clínica de Dispositivo Médico (DICD) pathway (RDC 837/2023) requires CEP approval before CONEP (for certain risk categories) and separate Licença de Importação under RDC 39. Realistic FPI: 6–10 months.
Mexico — COFEPRIS
COFEPRIS accepts parallel CEI + Comité de Investigación review. Protocol authorization plus Permiso Sanitario de Importación is required. Median FPI: 5–8 months.
Argentina — ANMAT
ANMAT clinical trial pathway (Disposición 6677/2010 + 4457/2006 for devices) requires federal ANMAT authorization plus provincial approvals (typically Buenos Aires + Santa Fe for a Rosario site network). CEI review runs in parallel. Median FPI on our last six ANMAT-authorized studies: 5.1 months.
Panama — MINSA
MINSA offers the fastest LATAM pathway for eligible early-feasibility studies via the Comité Nacional de Bioética de la Investigación (CNBI). Median FPI: 3–5 months. Best fit for first-in-human and early feasibility work when Colombia is not the primary site.
How to choose the right LATAM country (or combination)
- Speed to FPI: Panama > Colombia > Argentina ≈ Mexico > Brazil.
- Patient volume: Brazil > Mexico > Colombia > Argentina > Panama.
- Regulatory predictability: Colombia and Argentina lead on published timelines and stipulation transparency.
- Cost per enrolled patient: Colombia and Panama typically 30–50% below US benchmarks.
How bioaccess® runs multi-country LATAM programs
Global Trial Accelerators™ is bioaccess®’s single-accountable operating model for multi-country LATAM device studies. One project manager, one master timeline, harmonized site contracts, unified safety reporting, and one weekly sponsor readout across INVIMA, ANVISA, COFEPRIS, ANMAT, and MINSA.
For a scoped LATAM feasibility call, contact bioaccess®.